You are here

Article Text

Article menu
Download PDFPDF
Letter
Antibodies to β2 glycoprotein I and cardiolipin in SSc
  1. L Schoenroth1,
  2. M Fritzler1,
  3. L Lonzetti2,
  4. J-L Senécal2
  1. 1Faculty of Medicine, University of Calgary
  2. 2Department of Medicine, University of Montreal
  1. Correspondence to:
    Dr M Fritzler, 410B Heritage Medical Research Building, Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1;
    fritzler{at}ucalgary.ca

https://doi.org/10.1136/ard.61.2.183-a

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Systemic sclerosis (SSc) is a multisystem disease in which organ damage is characterised by fibrosis, microvascular occlusion, and proliferation of the vascular intima. The reported prevalence of anticardiolipin antibodies (aCL) in SSc varies from 0 to 25%,1–7 and reports of clinical associations have been variable.3,4,6,7 To our knowledge, only one study has examined antibodies to β2 glycoprotein I (aβ2GPI) in SSc and shown a correlation with pulmonary hypertension and raised mean pulmonary artery pressure.8 In our study we examined the frequency of aβ2GPI and aCL in SSc and Raynaud's phenomenon (RP).

    Twenty six patients with SSc (16 diffuse, 10 limited), 23 with RP, and 21 healthy volunteers (employees at the research facility) were included in this retrospective study. Informed consent was obtained. All 16 patients with diffuse SSc and one patient with limited SSc patients met American Rheumatism …

    View Full Text